Kate Therapeutics
Kevin Forrest is the Chief Executive Officer at Kate Therapeutics since September 2020. Prior to this role, Kevin served as President & CEO at Expansion Therapeutics, focusing on advancing treatments for severe RNA mediated diseases. With a background in Molecular Biology (PhD from Princeton University) and Biology (BS from Boston College), Kevin has held various executive positions at Cidara Therapeutics and 5AM Ventures.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.